Full Press Release Details
at AAOS 2012 Annual Meeting Shows
Equivalence to rhBMP-2 in Spinal Fusion;
Specifically to Orthopaedic Surgeons
BELGRADE, Mont. Feb. 10, 2012
- Bacterin International Holdings, Inc. (NYSE Amex: BONE),
a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, presented
at the American Academy of Orthopaedic Surgeons (AAOS) 2012 Annual Meeting in San Francisco, CA, its study showing OsteoSponge
equivalence to rhBMP-2 in spinal fusion.
The study, first presented at EuroSpine 2011 in Milan,
Italy in October of last year, was this past week featured at AAOS 2012, the largest gathering of companies displaying products
and services specifically for the orthopaedic surgeon.
Since OsteoSponge has been released, surgeons
have used Bacterin's bone graft implants more than 100,000 times, noting the product's unique handling properties, ability
to irrigate the site, and quick insertion of the OsteoSponge scaffold into a bony defect or a spinal interbody cage.
"AAOS is a great stage to get in front of orthopaedic
surgeons, who are the users of OsteoSponge, said Guy Cook, Bacterin's chairman and CEO. "Data from this study further
validates OsteoSponge's effectiveness in spinal fusion surgery, and we were pleased to present to and meet with a highly
Used in conjunction with the patients' own bone marrow
aspirate, OsteoSponge is a highly effective osteoinductive and osteoconductive bone scaffold that aids in spinal
fusion. The study was conducted in collaboration with researchers at the Salt Lake Orthopaedic Clinic, Spine Surgery of Salt
The two-year prospective, randomized, and blinded
clinical data showed OsteoSponge to be equivalent to rhBMP-2 in achieving an interbody fusion based upon radiographic
assessment, CT scans, and quality of life outcomes. Additionally, patients receiving the OsteoSponge graft reported statistically
significant less leg pain at one year relative to the rhBMP-2 group.
The abstract of this presentation, which evaluated
the effectiveness of Bacterin's OsteoSponge allograft for use in lumbar spinal fusion and entitled, "Lumbar Interbody
Fusion with OsteoSponge Demineralized Allograft in a PEEK Cage Compared to Fusion with rhBMP-2: Long Term Post-Operative
Assessment," was published in European Spine Journal (Volume 20, Supplement 4, 421-464).
About Bacterin International Holdings
Bacterin International Holdings, Inc. (NYSE Amex: BONE)
develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods
optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair
and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of
back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral
repair in knee and other joint surgeries.
Bacterin's Medical Device
division develops, employs, and licenses bioactive coatings for various medical device applications. Bacterin's strategic
coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination. For
further information, please visit www.bacterin.com.
Important Cautions Regarding Forward-looking Statements
This news release contains certain disclosures that may be
deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to
significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon
or refer to future events or conditions, or that include words such as "continue," "efforts," "expects,"
"anticipates," "intends," "plans," "believes," "estimates," "projects,"
"forecasts," "strategy," "will," "goal," "target," "prospects," "potential,"
"optimistic," "confident," "likely," "probable" or similar expressions or the negative
thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by
their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors,
including, among others: the Company's ability to launch beta and full product releases, the Company's ability to obtain FDA concurrence
use for anti-microbial coatings in a timely manner; the Company's ability to meet its obligations under existing and anticipated
contractual obligations; the Company's ability to develop, market, sell and distribute desirable applications, products and services
and to protect its intellectual property; the ability of the Company's sales force to achieve expected results; the ability of
the Company's customers to pay and the timeliness of such payments, particularly during recessionary periods; the Company's ability
to obtain financing as and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain
management and employees with appropriate skills and expertise; the impact of changes in market, legal and regulatory conditions
and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors are listed
in the Company's Annual Report on Form 10-K under the heading "Risk Factors." The Company undertakes no obligation to
release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events, except as required by law.
James Carbonara, Regional Vice President, 646-755-7412
Brett Maas, 646-536-7331